Total
0
Shares
Pacific Knowledge Systems' (ASX:PKS) - CEO, Ron van der Pluijm - The Market Herald
  • Pacific Knowledge Systems' (PKS) subsidiary, Pavilion Health, has signed a renewal agreement with Healthscope
  • Healthscope will continue using Pavilion's performance indicators of coding quality (PICQ) to measure the accuracy and consistency of patient-level health data
  • The contract is valued between $140,000 and $160,000 per annum
  • The agreement follows the recent renewal of Pavilion's other product -relative indicators of safety and quality
  • Healthscope Chief Commercial Officer, Jenny Patton, says data quality is the key to providing outstanding patient care
  • On the market this afternoon, PKS is up 4.39 per cent and is trading for 29.8 cents per share

Healthcare company Pacific Knowledge Systems' (PKS) subsidiary, Pavilion Health, has signed a renewal agreement with Healthscope to continue using PICQ.

Healthscope will continue using Pavilion's PICQ (performance indicators of coding quality), which measures the accuracy and consistency of the classification of patient-level health data.

The contract is valued between $140,000 and $160,000 per annum.

Healthscope also recently signed a renewal agreement for Pavilion Health's relative indicators of safety and quality (RISQ) product. RISQ tracks and measures the performance of clinical quality and safety for around 700,000 admissions across 43 hospitals.

RISQ and PICQ are software-as-a-service (SaaS) applications and are used to measure the integrity of clinically-classified health data to allow Healthscope to track and improve the quality of patient care.

Healthscope's Chief Commercial Officer, Jenny Patton, says data quality is the key to providing outstanding patient care.

"PICQ is part of our essential range of tools that we’ve relied on for several years, to help ensure the accuracy and timeliness of our patient data and help us deliver better patient outcomes," she told the market.

"PKS is pleased to work closely with a blue-chip customer like Healthscope in both its hospital as well as pathology operations," PKS Managing Director Ron van der Pluijm said.

"Improving the quality of data in healthcare is essential in order to improve patient outcomes as well as receive income and the renewal of PICQ will assist Healthscope greatly in this process," he added.

On the market this afternoon, PKS is up 4.39 per cent and is trading for 29.8 cents per share at 2:06 pm AEST.


Subscribe


PKS by the numbers
More From The Market Herald
PharmAust (ASX:PAA) awarded $881K grant for phase one monepantel trial

" PharmAust (ASX:PAA) awarded $881K grant for phase one monepantel trial

PharmAust (PAA) has been granted $881,085 for a phase one clinical trial of monepantel in patients with Motor Neurone Disease (MND).
CardieX (ASX:CDX) - CEO & Managing Director, Craig Cooper - The Market Herald

" CardieX (ASX:CDX) subsidiary granted European blood pressure patent

CardieX’s (CDX) subsidiary, ATCOR, has been granted a new patent by the European Patent Office (EPO) for its SphygmoCor technology.
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) sees improved results from two cancer trials

Cancer treatment company Immutep (IMM) has seen improving results from its cancer trials, INSIGHT-004 and TACTI-002.
Cann Global (CGB) appoints Marion Lesaffre as COO

" Purifloh (ASX:PO3) chairman resigns

Purifloh (PO3) Chairman, Bill Parfet, has announced his resignation from the Chairman position and stepped down as the Director of the Board.